GEN Exclusives

More »

GEN Poll

More »
May 07, 2013

Alzheimer’s Research

Baxter International’s drug candidate Gammagard is the latest Alzheimer’s therapeutic to fail in meeting its clinical endpoints. A number of other potential therapies have suffered similar fates. With these failures in mind, how can Alzheimer’s sufferers remain optimistic that relief is in sight?

Do you foresee a major breakthrough in the treatment of Alzheimer’s disease within the next 10 years?

Yes
 
  58.2%
No
 
  30.8%
Undecided
 
  11.0%

More Polls » View Results »

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?